Source:Seminars in Cancer Biology
Author(s): Anton Buzdin, Maxim Sorokin, Andrew Garazha, Marina Sekacheva, Ella Kim, Nikolay Zhukov, Ye Wang, Xinmin Li, Souvik Kar, Christian Hartmann, Amir Samii, Alf Giese, Nicolas Borisov
Anticancer target drugs (ATDs) specifically bind and inhibit molecular targets that play important roles in cancer development and progression, being deeply implicated in intracellular signaling pathways. To date, hundreds of different ATDs were approved for clinical use in the different countries. Compared to previous chemotherapy treatments, ATDs often demonstrate reduced side effects and increased efficiency, but also have higher costs. However, the efficiency of ATDs for the advanced stage tumors is still insufficient. Different ATDs have different mechanisms of action and are effective in different cohorts of patients. Personalized approaches are therefore needed to select the best ATD candidates for the individual patients. In this review, we focus on a new generation of biomarkers – molecular pathway activation – and on their applications for predicting individual tumor response to ATDs. The success in high throughput gene expression profiling and emergence of novel bioinformatic tools reinforced quick development of pathway related field of molecular biomedicine. The ability to quantitatively measure degree of a pathway activation using gene expression data has revolutionized this field and made the corresponding analysis quick, robust and inexpensive. This success was further enhanced by using machine learning algorithms for selection of the best biomarkers. We review here the current progress in translating these studies to clinical oncology and patient-oriented adjustment of cancer therapy.
https://ift.tt/2MddWmN
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου